The company will have their product launched for sales in early 2016 and already has a shareholder friendly $25M ATM offering in place to sell to the market during periods of high volatility.
Compare that to a 1.5 year delay for your TITXF investment that will no question need to dilute shareholders again to raise more money to be ready for commercialization. Not to mention the fact that the company has been working on the SPORT for three years and has yet to show an actual prototype and cites "competitive reasons" for not sharing the prototype or design of the robot. Complete lack of transparency.
TRXC will be at SAGES, has presented at 4 healthcare conferences in the past month, and is receiving constant inbound calls from surgeons and hospitals for their surgibot product. Compare that to TITXF who will be third to the market a full two years after TRXC established a large customer base. Not to mention lack of tactile feedback and patient side capability for the SPOrT, there is minimal value there, and there won't be much for a long time, until the company nears FDA approval 2.5 years from now. Ouch, long wait. TITXF has failed to bring a product to market, TRXC has not.
Also don't forget, TITXF loses plenty of money every quarter and has been doing so for years. It's a developmental company, nothing different from TRXC, except for the fact that TRXC has been generating revenue from a product that they never fully commercialized.
Their is no interest in the healthcare field for the SPORT when compared to the increasing interest the surgibot is receiving
News 
Market Data 
Discover 
